Related Experiment Videos

Pharmacologic considerations in the neonate with congenital heart disease

I L Calligaro1, C A Burman

  • 1Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA. caligaro@astro.temple.edu

Insights

Newer medications improve outcomes for infants with congenital heart disease. Understanding pharmacologic effects and pharmacokinetics optimizes treatment for cardiac failure and arrhythmias, enhancing survival rates.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Physiology

Background:

  • Congenital heart disease (CHD) presents unique challenges in infant cardiovascular development.
  • Understanding compensatory physiological changes is crucial for managing cardiac complications in infants with CHD.

Purpose of the Study:

  • To review advances in managing cardiac failure and arrhythmias in infants with CHD.
  • To highlight the role of newer pharmacologic agents in improving outcomes for pediatric cardiovascular conditions.

Main Methods:

  • Literature review of recent advancements in pediatric cardiology.
  • Analysis of pharmacologic data including effects, pharmacokinetics, and pharmacodynamics of relevant medications.

Main Results:

  • Newer therapeutic approaches have emerged for managing cardiac failure and arrhythmias in infants with CHD.
  • Improved understanding of drug actions leads to more precise medication use.

Conclusions:

  • Appropriate use of newer pharmacologic agents can significantly prolong survival in infants with CHD.
  • Enhanced knowledge of cardiovascular development and compensatory mechanisms improves patient outcomes.

Related Concept Videos